U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110103) titled 'Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC' on July 31.
Brief Summary: This is an open-label, single-arm, phase 2 study to evaluate the safety and efficacy of golidocitinib with PD-1 inhibitors as maintenance treatment in patients with previously untreated extensive-stage small cell lung cancer.
Study Start Date: Aug. 15
Study Type: INTERVENTIONAL
Condition:
SCLC
SCLC, Extensive Stage
Intervention:
DRUG: golidocitinib with PD-1 inhibitors
Dose escalation: 75/150mg golidocitinib with PD-1 inhibitors as maintenance treatment after 4 cycles of PD-1 inhibitors and chemotherapy.
Do...